Sanofi
Insulin glargine/lixisenatide fixed ratio formulation

Last updated:

Abstract:

The present invention refers to a pharmaceutical composition comprising (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) and compound (a) are present in a fixed ratio.

Status:
Grant
Type:

Utility

Filling date:

3 Apr 2019

Issue date:

8 Jun 2021